2020台灣生技月 Bio Taiwan 生物科技大展

2020 台灣生技月 南港展覽館

講師

ManysmarT Therapeutics Inc.

Biomedical EcoSystem development office in Taiwan, BEST

July 24th (Fri) 19:30 - 21:00 Entrepreneur Pitch 3

ManysmarT Therapeutics Inc.

Company Info

Name /ManysmarT Therapeutics Inc.

Address /4F, No. 236, Minzu W. Rd., Datong, Taipei, Taiwan.

Website /www.manysmart-t-cell.com

Presenter

Name /Liao Cheng Hao (Jack)

Title /R & D director

Email /lch@manysmart-t-cell.com

Telephone /(Work) +886-2-25996346

Fax /+886-2-25992471

Mobile /+886-917-244868

Company Type

Biotechnology

About the Company

Manysmart Therapeutics is a pre-clinical-stage allogeneic T cell therapy company focusing on cancer and infectious disease treatment. It was founded in December of 2018 with one granted Taiwan patent and three other patents in application and 1 million USD of Non-Dilutive Funding. Manysmart Therapeutics is positioned to deliver two T cell therapy candidates for clinical development in third quarter of 2021.

Brief Description of main products or services

Multiple Opportunities-Supplying T Cell Therapy (MOST Cell Therapy), an off-the-self T cell therapy platform based on γ9δ2-T cells, integrates CAR-T cell therapy, TCR-T cell therapy, Tumor Infiltrating Lymphocyte therapy, and Antibody therapy. Our astonishing ability to expand γ9δ2-T cells, a high-affinity CD16-Bi-specific T cell Engager (BiTE) which facilitating Antibody-Dependent T Cell-mediated Cytotoxicity, and TCR-BiTEs are our proprietary technologies to realize this platform for cancer/infectious disease treatment.

MOST Cell Therapy is a combination approach by using our proprietary technologies to effectively enhance therapeutic index of approved targeting agents (such as therapeutic antibodies) and to overcome antigen-loss problem in cancer treatment. MOST Cell Therapy has potential to pursue all the cancer indications and presently we focus on blood cancers and hepatocellular carcinoma.

A lead product from MOST Cell Therapy is a combination therapy of γ9δ2-T cells and approved blinatumomab (BLINCYTO), which potentially could reduce the number of blinatumomab-failed acute lymphocytic leukemia patients due to T cell deficiency, extramedullary diseases, and infection.

In addition, our astonishing ability in expanding γ9δ2-T cells provides the opportunity to produce large quantity and good quality of γ9δ2-T cells for companies who are interested in using γ9δ2-T cell as an allogeneic cell vector for their CAR/TCR cell products.

Contact Person

Name /Liao Cheng Hao (Jack)

Email /lch@manysmart-t-cell.com

Phone /(Work) +886-2-25996346